According to the American Cancer Society, 1 in 8 women will be diagnosed with breast cancer in their lifetime. ****** The 5-year survival rate of early detected cancer (Stage 1 or 2) is 96% compared to 65% when detected in later-stage cancer (Stage 3 or 4).

SecondReadAI™ uses Lunit INSIGHT, an artificial intelligence tool that provides a digital analysis of your mammogram and alerts the physician to suspicious areas

According to a clinical study, Radiologists using AI (Lunit INSIGHT) significantly increased their cancer detection rate compared to the radiologists unassisted by AI.***

In the same clinical study, Lunit INSIGHT, as a standalone product, outperformed Radiologists in detecting early-stage (T1 and node-negative) cancers by as much as 15%.**

***Clinical study reference https://www.thelancet.com/journals/landig/article/PIIS2589-7500(20)30003-0/fulltext

****** https://www.cancer.org/cancer/types/breast-cancer/about/how-common-is-breast-cancer.html#:~:text=Overall%2C%20the%20average%20risk%20of,will%20never%20have%20the%20disease.

Your AI results are interpreted by the radiologist and are included in the mammography report.

No additional time is required of the patient. The AI analysis is applied after the images have been sent to the radiologist. The processing time is about 90 seconds for each study.

Currently, SecondReadAI™ is not available for patients with breast implants as it has not been cleared through the FDA for use in these cases.

The AI upgrade is designed for standard mammography, though we remain committed to advancing our services and expanding eligibility in the future.

No. SecondReadAI™ exists to assist the radiologist by providing a detailed analysis of the mammogram to point out areas of concern, which the radiologist then factors into the interpretation of the exam.

We selected Lunit INSIGHT because it has proven high performance compared to other AI tools. In a recent publication comparing the performance of other AI tools, Lunit INSIGHT showed the best overall performance (Link to full publication in Jama Oncology)

This AI software cannot guarantee breast cancer detection with 100% accuracy.

Yes. Lunit INSIGHT is FDA cleared (510K)^ product and available for clinical use in the US.

^A 510 (k) is a premarket submission made to FDA to demonstrate that the device to be marketed is as safe and effective, that is, substantially equivalent, to a legally marketed device (section 513 (i) (1) (A) FD&C Act).

This AI software cannot guarantee breast cancer detection with 100% accuracy.

Lunit INSIGHT is widely used globally and is considered to be an accurate AI for mammography screening second look technology. It is currently used in some of the world’s largest breast screening settings to assist radiologists in early-stage cancer detection.

This AI software cannot guarantee breast cancer detection with 100% accuracy.

As with most new healthcare innovations,  SecondReadAI™ is not covered by insurance, but we are offering the service at a discounted rate of $80 from the original price of $90. (price subject to change)

Health reimbursement accounts such as HSAs and FSAs can be used a payment options.